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A total of 191 cons~utlve patients who underwent a successful PTCA were 
randomly assigned to re~ive eilher prolonged (heparin group, 100 pls.) of 
no postprocedure heparln (control group, 91 pts), The two treatment groups 
were comparable wdh respect to clinical and angtogt'aphic ¢heraoferistcs. 
Comlol gm~@ Hep,,n group p 
StenosmbelomPTCA (%1 74 t 16 72 t 15 ns 
S~a~f  PTCAI%I :~3 t 11 23 • 10 ns 
Mt, O tx~om FIrCA mm 09± 05 08$04 n~ 
MLDa~IFTCAmm ;~3 t 05 24 t 06 ns 
Stents 33136%) 33 (33%1 ns 
Myocan~l mla l~ 4% 3% ns 
C,kl~ 0 0 ns 
(:~e~th 1% 0 ns 
Va~ C0mlpb~ t % 3% nu 
Fou~ pal~nts in the Conllol grouP (4%) and 3 pal~nts m lhe hepann 
d~l  mine days aft~ me a-~m~on~ ~ vascu~r c o n ~  
in the ¢ontlro~ and ~ gn~u~ ~ m 1% an~t 3P= ot me patients, 
mspect,~/. 
Conctu~om: On~mn of ~ afte~ ~s lu l  PTCA w~h o~ 
slam ~l ion  in patmms wrlh ~ a~Kl unS~'~ble ~ d~l not mgn,f. 
Canl~ ~ me ~ of acute ~ compt~Cal~ns, ft a~ows Io~ 
eady sheam removal and pal~nt dmcharge and saves costs. It sheu~l be I~  
pa~y fo~ reut.~ paments. 
N~r!n-lndum~ 'n'~mmi~y~'~i Syndrome 
Con~tk~mg 1~-utamm~ Comnaw In~rven~ 
J.G Mofwam. K. Koflke-Marcha~ P.L Widow. S.G_ IEI~. EJ. Tapof 
Depa~ ot Can~,  Freedk:m~ Hospitad./.~ Heato~ 
~ T W , ~  Umle~ K~g~lom 
Hepann-mdUced ~ a sevem ~ synde~e me- 
dinted by a hepann-assooated plalelet-a¢lwalmg IgG, has bee~ ~lUe sludmd 
m lhe cot~ext el pefcet~-~m omona~ mtenmntion (PTC~). ~ 11/92 
and t(~J6, of 9486 patients (pts) who underwent PTCA. 69 (0.T3%) I~S (46 
ma~e; age68 ~+ 9 (SD) y) demonstrated tmpann-mduc~ I~e l~ aggregation 
assooated w~th absolute (94% of pts) o~ relative (5.6%) mrendx~cyto~-m~ 
Platelet cotmts lell by 60 ~: 18% from 234 ± 66K/.LtoS~ ± 40K~pL at 39  
2.8 days after commenong Lv. u~fractxmated hepann. ~ events 
OccmTed in 18.8%; lower limb artenal lhromtbosis. 4pls (1 requinng amputa- 
I~o~); lottel limb venous thrornbos~,, 5 pts; dialyze fistula mrombo~s. I I~: 
tatal mesentenc inlamtmn. I pt; recurrent inlracorona~/thrembus fon~abo~ 
w~h Q-wave ML I pt; and acute ~ 24 h) 11~ombos~ el I oill~e 24 ~ 
s-tents deployed (42%). w~h Q-wave MI in mis pt. P re t~-=~t  ~ asl:nnn 
(623%) of aspmn plus t~dol~line (28.9%). duration el hepann Irealment (23 
: 2.1 days), dose el hepann (1050 z 150 ./h) or prior hepann exposure 
(75.4%) where not ~ore  of degree ot fan in platetel count of occun-enoe 
of throcnbot)c events. ~ i c  events occurred in 3 of 19 pLs (15.8~,) 
who recetved aboximab and in 9 ol 50 pts (18%) who did not (p : NS) 
NO adddmnal thrombol¢ events oocurred among pts m where unfmctmnated 
hepann was subsMuted troth low mofecumr we~ht hepann (after excluding 
crossreactnnty; n = 7), a~Datroban (n = 1) or ancrod (n = 1). Skin hectors 
OCCUrred in 1 of 14 pls commenced on coumadin. 
Cot~usron: Hepann-mduced thrombocytopema complicating Coronary in- 
lenrentton results in a high hequency ot malor artenal anQ venous thrombct~ 
events, irrespectnm of (:Lose and dorabon of hepann, and despde Optimal 
antiplatelet herapy. 
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R.L. Wilensky, J.oF. Tanguay. S. Ire, A.L. Bartorelli, J Moses. D O. Williams. 
TA. Bucher. P. Gallant, H Wu, J.J. Popma. N, We~srnann, G.S. Mintz. 
A.V. Kaplan. M.B. Leon. Washington Hospital Center, Washington. DC. USA 
Local delivery, ot hepann is a promising approach to reduce in-slant testa- 
nests. Slant-lumen volume as measured by intravaScular ultrasound (IVUS) 
provides a means to efticiently evaluate the impact of new therapies on 
in-stent restonosis We studied the impact of locally delivered heparin on 
in-stent rostenosis as measured b~., IVUS in the HIPS study, a multi-cen- 
ter, randomized conmlled trial. A total of 179 patients were randomized to 
receive heparin (5000 U in 5 ml) either intracoronary tic/control) via the 
guide catheter or intramural via the InfusaSleevo (LocalMed, Inc.) pdo: to 
single Palmaz-Schatz slant placement. Baseline demographic, clinical and 
angiogrephic parameters were evenly distributed with the exception of initial 
Minimal Luminal Diameter, 1.12 ± 0.34 vs 0,99 ± 0.37 ram, in the ic/control 
and intramural groups respectively (p .  0.03), Core ang~o~ral~l~ labomlo~ 
evaluation of the intramural group rav~aNK118 NHLBI Gra¢le ~ 
tollow~ng inilial PTCA ot wh~h 1 progreued toflowtng local h(~Ntf~ thera~/. 
there were no significant d~fter~-,;,~ in the EUC d~mc~o~ m the two groups 
pnor fo flt0nt placement, 33% (P/control) vs 29% (irtramural) l~oo~k~ral 
o~t¢omes as mea=um0 W timbal, angiogra~ and hqJS criterta were ~m- 
ilar between, ~ (cltn¢,l au~= 98,9 v~ 98~ pttter~ m the ¢,~ntm 
ar~ intramural grou~ mt~"t~y) ,  In.lx~q~l ~ m~.  1,1% (wcomml) 
v~ 1-2% (intramural) and 30 ¢lav coe~l~ ( r~e mlpo~e<l) w~m ~m~. 
tar S~ month clinical, ang~grapt~ and IVU$ !ollow,t~o will be O0mlple~ m 
J~ngaw 1998, 
Conc/~.- Local delivery ot I~pann v~ the ~,aS lee~e m 
and Mle, The ~Ct  ot 11~ mempy on n~no~ ~lowmg mer~ l~acem~ 
c~ten'nine~ by an~u~¢ and IVU$ paramelera wdl be ~ 
mmm1=In m~1 ~11-'1~mm1~In A¢11vlty 0urU~ 
l~mlan~u!'rnlnilumlmll Comnmy 
Anglo,fury 
WK Laskey, K Zawac~0, R Lm~, N. Calamuno, D. McCanon, WG Herzog. 
t /nn~ ot Ma./~n~ M~V.a /S~ Ba/~mom Ma~ar~ USA 
Back~'oun(t The mmb~tory enecm el hepann (H) on me coagulation symem 
am medialed by I~e ~ ¢4 an~l~mmbm III (AT III). L3me is ke~m~ of 
Ihe a#e~ el !~1~'~ H on I rans .¢a~ AT III acrid/and no ~ m 
avadab~ on l~ma-¢a~0Bac AT III followlng leoal H deINery dunng PTCA 
~#nmo~: We analyzeO pat t i  symm¢ ammai (SA) and co~t~,V sinus 
(CS) beoed samples m 9 pa~lei~ undmgomg PTCA. AT I11and Fp~ a ma,.ke~ 
of 8~d~n acUvey, was measmed p~or to com.~ary mofnmmntmmn (~) .  
5 ~ foflowWtg 10,000 traits of ~ H (SH), 5 minules after 
completion of PTCA (pro LH), a~d 5 minutes after 4,000 uftit= of H c le~d 
to ff~e PTCA uite wa a ~ infusion catheter (peru LH). 
ResuRs: 
base SH ~e LH post I.H 
CSAT Ill (%) 71 t 16 (~9 ~: 16 75 ± 27 97 i 23 a 
AT III |%1 67 ~: 19 64 t 25 79 ~: 20  80 t- !~  
CS FpA (n~1111) 100  t 2 I 5.9 ~: 3.8 22  ¢ 3~. 1 5 ± 2%: 
SA F~A (n~m~ 97 : 19  5.B ~: 38  4B  ¢ 34  46  ~r 26  d 
, ~ . . . . .  ~ =p-  0 ( ]~]01 ,°=p 0001byANOVAi  
~ :  1) SH donng PTCA results m oL~ectable i,-,~ieases m born 
SA & CS AT nl ~ and decreases in SA & CS FpA and 2) I.H results 
in fmlher mcm.ased local (CS) AT Ill aclnnty and dimlmshed FpA release. 
These results support enhanced and ~e-speof¢ hepann actn,tly when ap- 
rr,r,stered locally. 
~ D o e =  ~ Wire Intravenous .epa~n 
Produces any Angiogmphk: hnpmmm~t in 
Patients Admitted With Unstable Angina? 
F. Cura. R. Pimmo, L. Guzman, L Pallia. J. Fernandez. G. Marchefti, 
A Palacios, J. I~elam~. Instn~to CardloYasc'u~r de Buenos A/res, , ~  
The ~esence of ~racomnaw n~ombus is a c~mmon ~l ing  m pe~ents (~s) 
un~ff~:,r,~ can~an came~mza~n de~g unstable angina (UA). Coronary 
(PTCA) dunng this s~ing has been as~c~ted w~ a s~r,T,;~i 
inc~mem of complication. Tempera~ tream~t w~m intravenous (IV) hep- 
ann prior to proceed with the PTCA has been postulated as a safer way in 
thin pts. The i~.'mose of mrs stuo'y was to evatuate me ~ c t '~ ,~ 
alter the l ' re~ ~ Ilepann during 48 to ~ hours (hnS) in 10ts Brimmed 
with UP,, From 08/96 to 08/97. we prospectively evaluale 23 ~s w~h UA who 
had the ltrsl Coronary ang~grem (angm) wdhin 24 hrs (mean of 17.8 ± 6.9 
hm) of the last ~ of class IV angina and the second ang~o between 
48 to 96 hrs (mean of 533 ± 17.4 hrs) after the treatment of IV heparin, 
The presence 01 thren~us, thrembus SCOre. the TIMI flow, the frame count 
measurement, percentage of stenoszs. ACC score and all the morphologic 
characteristics were evaluated in both angto by two blinded observers. (An- 
giographic thrombus was classified as 0 = no thrombus, 1 = haziness, 2--4 
= definitnte thfomb*us with size < 0.5, 0.5-1.5, > 1.5 the reference diameter, 
respectn/ely). Both anglo did not show any stgnif~ant changes. 
Fm~t a ~ m  Second angTogram p value 
Thrombus (+) 565% 56.5% NS 
Thrombus Score 2.23 • 1.3 207  _~ 1 04 0.52. 
TIMI flow 2.65 ± 0.57 265  ± 0.64 NS 
Frame Count 50.3 • 33 40.4 ± 29 0.29 
Thrombus Size 363  ~: 1.7 mm 2.6 ± 1.7 mm 027 
% Stenosm 69 ± 7.8% 679 ~ 10 8% 069 
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